Home > Insider Trading > Filing (0000899243-22-027423)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1596946	Quotient Ltd	QTNT	In Vitro & In Vivo Diagnostic Substances (2835)	264719797

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1823186	Isabelle Buckle	C/O Quotient Limited, Business Park Terre Bonne, Route De Crassier 13 Eysins V8 1262		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares	Disposition	2022-07-31	2,479	$0.00	33,735	No	4	S	Direct
Ordinary Shares	Acquisiton	2022-07-31	6,917	$0.00	36,214	No	4	M	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	M	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Ordinary Shares	Restricted Stock Units	Disposition	2022-07-31	6,917	$0.00	6,917	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
6,917			No	4	M	Direct

Reported Derivative Holdings

Sec. Name	Sec. Type	Price	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Ordinary Shares	Ordinary Share Option(Right to Buy)	$4.81	2030-09-01	20,790	20,790	Direct
Ordinary Shares	Ordinary Share Option(Right to Buy)	$4.81	2030-09-01	2,171	2,171	Direct
Ordinary Shares	Ordinary Share Option(Right to Buy)	$4.55	2030-10-31	13,611	13,611	Direct
Ordinary Shares	Ordinary Share Option(Right to Buy)	$2.53	2031-10-31	24,040	24,040	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2030-09-01	20,790	20,790	Direct
2030-09-01	2,171	2,171	Direct
2030-10-31	13,611	13,611	Direct
2031-10-31	24,040	24,040	Direct

Footnotes

Restricted Stock Units convert into ordinary shares on a one-for-one basis.
6,930 options vested on September 1, 2021 and remain exercisable, and the remaining 13,860 options will vest in two equal installments on September 1, 2022 and September 2, 2023.
724 options vested on October 31, 2021 and remain exercisable, and the remaining 723 options will vest on October 31, 2022.
All 13,611 options have vested and remain exercisable.
On October 31, 2021, the Reporting Person was granted 27,668 restricted stock units, of which 20,751 have vested and have converted into ordinary shares. The remaining 6,917 restricted stock units will vest on October 31, 2022.
The options vest and become exercisable on October 31, 2022.
The sale reported on this Form 4 is a sale to cover taxes arising from the vesting and settlement of RSU awards. This sale is mandated by the Reporting Person's election to fund such taxes by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer.